AU2015256383B2 - Methods of treating incontinence and other sphincter deficiency disorders - Google Patents

Methods of treating incontinence and other sphincter deficiency disorders Download PDF

Info

Publication number
AU2015256383B2
AU2015256383B2 AU2015256383A AU2015256383A AU2015256383B2 AU 2015256383 B2 AU2015256383 B2 AU 2015256383B2 AU 2015256383 A AU2015256383 A AU 2015256383A AU 2015256383 A AU2015256383 A AU 2015256383A AU 2015256383 B2 AU2015256383 B2 AU 2015256383B2
Authority
AU
Australia
Prior art keywords
sphincter
sdf
incontinence
disorder
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015256383A
Other languages
English (en)
Other versions
AU2015256383A1 (en
Inventor
James K. WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University Health Sciences
Original Assignee
Wake Forest University Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University Health Sciences filed Critical Wake Forest University Health Sciences
Publication of AU2015256383A1 publication Critical patent/AU2015256383A1/en
Application granted granted Critical
Publication of AU2015256383B2 publication Critical patent/AU2015256383B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015256383A 2014-05-08 2015-04-30 Methods of treating incontinence and other sphincter deficiency disorders Active AU2015256383B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990190P 2014-05-08 2014-05-08
US61/990,190 2014-05-08
PCT/US2015/028490 WO2015171417A1 (en) 2014-05-08 2015-04-30 Methods of treating incontinence and other sphincter deficiency disorders

Publications (2)

Publication Number Publication Date
AU2015256383A1 AU2015256383A1 (en) 2017-01-05
AU2015256383B2 true AU2015256383B2 (en) 2020-05-21

Family

ID=54392862

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015256383A Active AU2015256383B2 (en) 2014-05-08 2015-04-30 Methods of treating incontinence and other sphincter deficiency disorders

Country Status (6)

Country Link
US (2) US10420818B2 (enExample)
EP (1) EP3139945B1 (enExample)
JP (1) JP2017514875A (enExample)
AU (1) AU2015256383B2 (enExample)
CA (1) CA2946761C (enExample)
WO (1) WO2015171417A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3139945B1 (en) 2014-05-08 2025-08-27 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
WO2019032930A1 (en) * 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
CN114159471A (zh) * 2020-09-11 2022-03-11 永立荣生医股份有限公司 包括羊水干细胞球的医药组合物及其治疗尿失禁的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032075A1 (en) * 2004-09-24 2006-03-30 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
US20080311219A1 (en) * 2007-06-15 2008-12-18 Anna Gosiewska Tissue Fragment Compositions for the Treatment of Incontinence
US20110081323A1 (en) * 2005-09-21 2011-04-07 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US8435953B2 (en) * 2007-11-07 2013-05-07 Yasuhiko Tabata Sustained release composition containing SDF-1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US311219A (en) 1885-01-27 Mechanical toy
JP2609851B2 (ja) 1986-09-04 1997-05-14 悦子 柿崎 徐放性注射剤
US5385561A (en) 1994-01-18 1995-01-31 Bard International, Inc. Apparatus and method for injecting a viscous material into the tissue of a patient
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
US5588960A (en) 1994-12-01 1996-12-31 Vidamed, Inc. Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence
US5925629A (en) 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
MXPA02012067A (es) 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
WO2003005889A2 (en) 2001-07-10 2003-01-23 Ams Research Corporation Surgical kit for treating prostate tissue
WO2007087367A2 (en) 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US7598028B2 (en) 2006-11-28 2009-10-06 The Regents Of The University Of Michigan Compositions and methods for detecting and treating prostate disorders
US20100272679A1 (en) * 2007-12-14 2010-10-28 Penn Marc S Compositions and methods of promoting wound healing
CA2733468C (en) 2008-08-09 2017-12-05 Massachusetts Institute Of Technology Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
WO2011026041A2 (en) 2009-08-28 2011-03-03 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US9308277B2 (en) * 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP3139945B1 (en) 2014-05-08 2025-08-27 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032075A1 (en) * 2004-09-24 2006-03-30 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
US20110081323A1 (en) * 2005-09-21 2011-04-07 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US20080311219A1 (en) * 2007-06-15 2008-12-18 Anna Gosiewska Tissue Fragment Compositions for the Treatment of Incontinence
US8435953B2 (en) * 2007-11-07 2013-05-07 Yasuhiko Tabata Sustained release composition containing SDF-1

Also Published As

Publication number Publication date
US11160848B2 (en) 2021-11-02
US20190365860A1 (en) 2019-12-05
CA2946761A1 (en) 2015-11-12
AU2015256383A1 (en) 2017-01-05
JP2017514875A (ja) 2017-06-08
WO2015171417A1 (en) 2015-11-12
EP3139945A4 (en) 2017-11-29
CA2946761C (en) 2023-08-22
US10420818B2 (en) 2019-09-24
US20170106050A1 (en) 2017-04-20
NZ727292A (en) 2024-03-22
EP3139945A1 (en) 2017-03-15
EP3139945B1 (en) 2025-08-27

Similar Documents

Publication Publication Date Title
US11160848B2 (en) Methods of treating gastrointestinal sphincter deficiency disorders
KR102559262B1 (ko) 심근증, 진구성 심근경색 및 만성심부전의 치료약
KR102146815B1 (ko) Hmgb1 단편을 이용한 신규 심근경색의 치료법
Heber–Katz et al. The scarless heart and the MRL mouse
CN1824289A (zh) P物质用于间充质干细胞的动员或增殖以及用于伤口愈合或促进伤口愈合的用途
JP2009538274A (ja) Ｃｘｃｌ１３またはｃｘｃｒ５のアンタゴニストの創傷または線維症疾患の治療のための使用
Oh et al. Functional and histological evidence for the targeted therapy using biocompatible polycaprolactone beads and autologous myoblasts in a dog model of fecal incontinence
Deppen et al. A swine hind limb ischemia model useful for testing peripheral artery disease therapeutics
JP2020514305A (ja) ファーバー病を治療するための組成物及び方法
US20220105156A1 (en) Methods of treatment for kidney disease
Tu et al. Somatic Braf V600E mutation in the cerebral endothelium induces brain arteriovenous malformations
Plair et al. Regenerative medicine for anal incontinence: A review of regenerative therapies beyond cells
Williams et al. Methods of treating incontinence and other sphincter deficiency disorders
JP2020518644A (ja) 虚血組織を治療するための方法
JP7514563B2 (ja) オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物
US11654181B2 (en) Use of CXCL12 for therapy after prostate surgery
KR20140041263A (ko) 말초혈액 단핵세포를 유효성분으로 포함하는 예방 또는 치료용 약제학적 조성물
US20180280434A1 (en) Sequential application of macrophages for wound healing
US12491211B2 (en) Therapy for interstitial cystitis by pluripotent stem cells
ES2903411T3 (es) AMD3100 para el tratamiento y/o la prevención de caquexia, y composición farmacéutica del mismo
CN115531515A (zh) 肿瘤靶向药物及其应用
Zhang et al. e0192 A metaanalysis of right ventricular septum pacing
Katz et al. The scarless heart and the MRL mouse
JP2008307053A (ja) 若年型糖尿病の治療
HK1138315B (en) Expansion method for adult stem cells from blood, particularly peripheral blood, and relative application in medical field

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)